Fore Pharma announced the results of its Osteoporosis patients study in a new report ‘Europe Osteoporosis Epidemiology and Patient Flow Analysis - 2017’.
The report provides insights into Osteoporosis epidemiology, Osteoporosis diagnosed patients, and Osteoporosis treatment rate for EU5 pharmaceutical markets. The study measures key indicators such as prevalence of Osteoporosis derived from epidemiological analysis, percentage of patients diagnosed with Osteoporosis, and percentage of patients treated with a therapy.
The study helps executives estimate Osteoporosis market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
The report provides estimates and forecasts of Osteoporosis prevalence, Osteoporosis diagnosis rate, and Osteoporosis treatment rate for the period 2016 - 2025. The information is presented by leading geographies including Germany, France, Spain, Italy, and UK. The study design is based on interpretation and analysis of data collected from physicians via primary interviews, registries, scientific journals, literatures, government databases and other secondary sources.
Key Features of the Report: - Osteoporosis Patient Flow - Osteoporosis Prevalence - Osteoporosis Diagnosed Patients - Osteoporosis Treated Patients
Our reports have been used by over 10K customers, including:
‘Adult-onset Still’s Disease – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical, and forecasted Adult-onset Still’s Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Geographies Covered •...
Dermatomyositis Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Dermatomyositis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Dermatomyositis Clinical trials scenario.This report provides top line data relating to the clinical trials...
Collagenase 3 - Pipeline Review, H2 2020 Summary Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Collagenase...
Osteoarthritis Pain Drug Market Research Report by Drug Class (Corticosteriods, NSAIDs, and Viscosupplementation), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel - Global Forecast to 2025 - Cumulative Impact of COVID-19 Market Statistics: The report provides market sizing and...
Gouty Arthritis (Gout) - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis - Pipeline Review, H2 2020, provides an overview of the Gouty Arthritis (Musculoskeletal Disorders) pipeline landscape. Gout is a type of arthritis where swelling...
Rheumatoid Arthritis - Epidemiology Forecast to 2029 Summary Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity.The condition manifests itself in multiple joints in the body (Mayo Clinic, 2019; Centers...
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.